American Tower Corp vs Quest Diagnostics Inc — how do they compare? American Tower Corp trades at $170.43 (market cap $79.00B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: American Tower Corp is far larger — about 3× Quest Diagnostics Inc's market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| AMT | DGX | |
|---|---|---|
Market Cap | $79.00B | $26.21B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $238.50 |
52-Week Low | $162.11 | $173.49 |
Enterprise Value | $122.53B | $31.97B |
Dividend Yield | 4.12% | 1.45% |
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $170.48, up 0.81% with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals despite analyst optimism, with 79.6% buy ratings and a $206.17 consensus price target representing 21% upside potential. Recent Q2 2026 results demonstrated accelerated lease contract growth and raised full-year guidance.
AMT presents a compelling investment case with strong revenue visibility from telecom infrastructure demand and 5G/6G expansion cycles. However, high debt levels and interest rate sensitivity pose significant risks. The stock offers defensive characteristics through recurring revenue streams but faces headwinds from DISH Network churn and capital expenditure requirements.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Trailing returns across standard periods
Latest headlines on both assets
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →